Original articles

Value of new-type serum fibrosis-related biomarkers level in diagnosing IgG4-related disease

Expand
  • Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2019-01-10

  Online published: 2019-06-25

Abstract

Objective: To explore serological biomarkers which can be used for diagnosing IgG4-related diseases (IgG4-RD) and to analyze its correlation with involvement of IgG4-RD and patients' response to corticosteroid therapy. Methods: Seventy-two patients with untreated IgG4-RD from January 2015 to January 2019 were enrolled. The serum concentrations of growth differentiation factor 15 (GDF-15), CC chemokine ligand 2 (CCL2), hyaluronic acid (HA), amino-terminal propeptide of type Ⅲ procollagen (PⅢNP), and tissue inhibitor of metalloproteinases 1 (TIMP-1) were measured by enzyme-linked immunosorbent assay. The enhanced liver fibrosis (ELF) score was calculated from the TIMP-1, PⅢNP and HA values. The value of these biomarkers in reflecting the degree of tissue fibrosis and extent of organ involvement was assessed. Results: Compared with healthy controls, patients with IgG4-RD had significantly elevated serum concentrati-ons of GDF-15, HA, PⅢNP, and TIMP-1; the average concentrations of CCL2, HA, PⅢNP and TIMP-1 were 1 121 pg/mL, 398 pg/mL, 87.2 ng/mL and 211 ng/mL, respectively. The ELF score of IgG4-RD patients was also significantly elevated (11.2). Among them, serum GDF-15 of 666 pg/mL distinguished most efficiently patients with IgG4-RD from healthy controls (area under ROC 0.92, sensitivity 77.8%, specificity 100%). Conclusions: New-type serological biomarker GDF-15 and CCL2 have substantial clinical value in diagnosis of IgG4-RD but can not reflect the severity of organ involvement and degree of fibrosis, or cannot be served as criteria of outcome of corticosteroid treatment.

Cite this article

ZHOU Xinyun, CHEN Hui, SHEN Lisong . Value of new-type serum fibrosis-related biomarkers level in diagnosing IgG4-related disease[J]. Journal of Diagnostics Concepts & Practice, 2019 , 18(03) : 329 -333 . DOI: 10.16150/j.1671-2870.2019.03.016

References

[1] Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease[J]. Lancet, 2015, 385(9976):1460-1471.
[2] Wallace ZS, Deshpande V, Mattoo H, et al. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients[J]. Arthritis Rheumatol, 2015, 67(9):2466-2475.
[3] Ohta N, Kurakami K, Ishida A, et al. Roles of TGF-beta and periostin in fibrosclerosis in patients with IgG4-rela-ted diseases[J]. Acta Otolaryngol, 2013, 133(12):1322-1327.
[4] Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease[J]. Arthritis Rheum, 2012, 64(1):254-263.
[5] Akiyama M, Yasuoka H, Yoshimoto K, et al. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease[J]. Ann Rheum Dis, 2018, 77(9):1386-1387.
[6] Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease[J]. Gut, 2010, 59(9):1245-1251.
[7] Della-Torre E, Feeney E, Deshpande V, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease[J]. Ann Rheum Dis, 2015, 74(12):2236-2243.
[8] Abignano G, Cuomo G, Buch MH, et al. The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis[J]. Ann Rheum Dis, 2014, 73(2):420-427.
[9] Wu M, Baron M, Pedroza C, et al. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts[J]. Arthritis Rheumatol, 2017, 69(9):1871-1878.
[10] Yalçinkaya Y, Çinar S, Artim-Esen B, et al. The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predomi-nantly associated with fibrotic manifestations[J]. Clin Exp Rheumatol, 2016, 34 Suppl 100(5):110-114.
[11] Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012, 22(1):21-30.
[12] Umehara H, Okazaki K, Nakamura T, et al. Current approach to the diagnosis of IgG4-related disease - Combination of comprehensive diagnostic and organ-specific criteria[J]. Mod Rheumatol, 2017, 27(3):381-391.
[13] Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012[J]. J Hepatobiliary Pancreat Sci, 2012, 19(5):536-542.
[14] Goto H, Takahira M, Azumi A, et al. Diagnostic criteria for IgG4-related ophthalmic disease[J]. Jpn J Ophthalmol, 2015, 59(1):1-7.
[15] Matsui S, Yamamoto H, Minamoto S, et al. Proposed diagnostic criteria for IgG4-related respiratory disease[J]. Respir Investig, 2016, 54(2):130-132.
[16] Lichtinghagen R, Pietsch D, Bantel H, et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influe-nce factors and proposed cut-off values[J]. J Hepatol, 2013, 59(2):236-242.
[17] de Jager SC, Bermúdez B, Bot I, et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis[J]. J Exp Med, 2011, 208(2):217-225.
[18] Sierra-Filardi E, Nieto C, Domínguez-Soto A, et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile[J]. J Immunol, 2014, 192(8):3858-3867.
[19] Furukawa S, Moriyama M, Tanaka A, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's di-sease[J]. Clin Immunol, 2015, 156(1):9-18.
Outlines

/